Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVFree Report) in a report released on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

Shares of Nabriva Therapeutics stock opened at $0.35 on Friday. Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The company has a market cap of $11.21 million, a price-to-earnings ratio of -0.02 and a beta of 1.53. The business’s 50 day moving average price is $0.44 and its 200 day moving average price is $1.00.

Institutional Investors Weigh In On Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRVFree Report) by 102.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 795,938 shares of the biotechnology company’s stock after purchasing an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent SEC filing. 0.27% of the stock is owned by hedge funds and other institutional investors.

Nabriva Therapeutics Company Profile

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

Read More

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.